Pyxis Oncology Inc (PYXS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2022 | 06-2022 | 03-2022 | 12-2021 | 09-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -84,616 | -56,942 | -31,380 | -75,975 | -59,146 |
| Depreciation Amortization | 517 | 317 | 158 | 647 | 489 |
| Accounts payable and accrued liabilities | -6,443 | -4,131 | -9,896 | 4,643 | 610 |
| Other Working Capital | -570 | -2,731 | -93 | 6,676 | 5,852 |
| Other Operating Activity | 19,164 | 12,096 | 13,532 | 28,683 | 29,038 |
| Operating Cash Flow | $-71,948 | $-51,391 | $-27,679 | $-35,326 | $-23,157 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -4,541 | -275 | -146 | -540 | -540 |
| Purchase Of Investment | N/A | N/A | N/A | -50 | -50 |
| Investing Cash Flow | $-4,541 | $-275 | $-146 | $-590 | $-590 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 183 | 177 | 176 | 152,463 | 14 |
| Other Financing Activity | 0 | 0 | 0 | 151,581 | 149,130 |
| Financing Cash Flow | $183 | $177 | $176 | $304,044 | $149,144 |
| Beginning Cash Position | 276,316 | 276,316 | 276,316 | 8,188 | 8,189 |
| End Cash Position | 200,010 | 224,827 | 248,667 | 276,316 | 133,586 |
| Net Cash Flow | $-76,306 | $-51,489 | $-27,649 | $268,128 | $125,397 |
| Free Cash Flow | |||||
| Operating Cash Flow | -71,948 | -51,391 | -27,679 | -35,326 | -23,157 |
| Capital Expenditure | -4,541 | -275 | -146 | -540 | -540 |
| Free Cash Flow | -76,489 | -51,666 | -27,825 | -35,866 | -23,697 |